SCHEMBL5116602

SCHEMBL5116602

C#Cc1ccsc1-c1nc2c(C)cccn2c1NC(C)c1ccccc1.c1cc2cc-2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 12/20 0.40
MAPT P10636 9/20 0.40
TP53 P04637 7/20 0.40
SMN1; SMN2 Q16637 5/20 0.38
NR1H4 Q96RI1 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.36
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122972 0.85 ATP4A (0.40) NR1H4MEN1CYP1A2CYP3A4CYP2D6
SCHEMBL5129230 0.84 NR1H4 (0.44) GAAMAPTTP53SMN1; SMN2NR1H4
SCHEMBL5127885 0.84 MAPK14 (0.42) SMN1; SMN2NR1H4NPC1RAB9AMEN1
SCHEMBL5128154 0.82 NR1H4 (0.59) GAATP53SMN1; SMN2NR1H4KDM4E
SCHEMBL5122233 0.82 BRD4 (0.50) GAAMAPTTP53SMN1; SMN2NR1H4
SCHEMBL5122906 0.79 NR1H4 (0.40) GAAMAPTTP53SMN1; SMN2NR1H4
SCHEMBL5128546 0.77 ALOX5 (0.41) GAAMAPTTP53SMN1; SMN2KDM4E
SCHEMBL5121126 0.76 PLAU (0.42) GAAMAPTTP53SMN1; SMN2NR1H4
SCHEMBL5123835 0.76 NR1H4 (0.41) GAAMAPTTP53SMN1; SMN2NR1H4
SCHEMBL5118779 0.69 CYP1A2 (0.39) GAAMAPTTP53KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS GAA 234/4885MAPT 707/4885TP53 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.